CDXS News and Press, Codexis Inc. From 04/18/22

Codexis is a protein engineering company based in the United States that markets its products globally. The protein engineering industry is experiencing rapid growth as increased investment signals great potential for companies operating in the market. Codexis has experienced loss...

Molecular Assemblies has pioneered Fully Enzymatic Synthesis™ (or FES™) technology with an in-process purification step to overcome the length, purity, and accuracy limitations of the current chemical DNA synthesis method The collaboration between Molecular Ass...

REDWOOD CITY, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that management will participate in both a panel discussion and a fireside chat at the Cowen 42 nd A...

The following slide deck was published by Codexis, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Codexis, Inc. 2021 Q4 - Results - Earnings Call Presentation

Codexis, Inc. (CDXS) Q4 2021 Earnings Conference Call February 24, 2022 16:30 ET Company Participants Brendan Strong - Argot Partners John Nicols - President & Chief Executive Officer Ross Taylor - Senior Vice President & Chief Financial Officer Conference Call Participants Brandon Co...

Codexis press release (NASDAQ:CDXS): Q4 GAAP EPS of -$0.16 beats by $0.04. Revenue of $24.5M (+16.7% Y/Y) beats by $1.35M. Outlook: Company Guides to 2022 Total Revenues of $152-$158M (consensus: $122.55M); Product Revenues of $112-$118M Shares +5.78% AH For further details see: ...

Record Annual Total Revenue of $104.8M, Representing Eighth Consecutive Year of Revenue Growth Company Guides to 2022 Total Revenues of $152-$158M; Product Revenues of $112-$118M REDWOOD CITY, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading e...

REDWOOD CITY, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that it will report its fourth quarter and fiscal year 2021 financial results on Thursday, February 24, 2022, ...

REDWOOD CITY, Calif., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation (ODD) for CD...

Two sample Breakout Stocks for Week 52 with better than 10% short-term upside potential and a Dow stock pick. This past week, two stocks beat 10% peak gains in FLGT +19.1% and DYAI +13.8% with Momentum Gauge® values improving through the week. Following the Daily Momentum Gau...